Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Beta This is a new resource - your feedback will help us improve it. Learn More.

Corporate Integrity Agreement with EyePoint, Inc.

Active  |  Effective on  |  Duration 5 years
Location
Watertown, MA
Estimated Completion
July 2031
Settlement Amount
$4,678,981

DOCUMENTS

AGREEMENT PRESS RELEASE

EyePoint Pharmaceuticals to Pay $4.6 Million to Resolve False Claims Act Allegations

Published by the United States Department of Justice | View article on www.justice.gov

Published by the United States Department of Justice | View article on www.justice.gov

Eyepoint Pharmaceuticals, Inc., (EyePoint) headquartered in Massachusetts, has agreed to pay the United States $ 4,657,463.18 to resolve allegations that it violated the False Claims Act by paying kickbacks to certain Ambulatory Service Centers (ASCs) to induce those ASCs to purchase and dispense DEXYCU, an injectable drug approved for the treatment of ocular inflammation following cataract surgery, between January 1, 2019 and March 1, 2023.

Report Type
Corporate Integrity Agreement
Category
Other
Tags
Medicaid Prescription Drug Financial Stewardship Quality of Care Medicare C Medicare D Elderly People With Disabilities